The future of artemisinins: natural, synthetic or recombinant?
Tóm tắt
Artemisinins are the most important anti-malarial drugs in use today, but are more costly than previous anti-malarials and production and price tend to fluctuate. Alternative ways of producing artemisinins are discussed here in the light of a recent paper in BMC Biotechnology on improving the yield of the precursor, artemisinic acid, in genetically engineered yeast.
Tài liệu tham khảo
World Heath Organization: Guidelines for the Treatment of Malaria. WHO/HTM/MAL/2006.1108.
Ro DK, Ouellet M, Paradise EM, Burd H, Eng D, Paddon CJ, Newman JD, Keasling JD: Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid. BMC Biotechnol. 2008, 8: 83-10.1186/1472-6750-8-83.
Meshnick SR, Jefford CW, Posner GH, Avery MA, Peters W: Second-generation antimalarial endoperoxides. Parasitol Today. 1996, 12: 79-82. 10.1016/0169-4758(96)80660-0.
Kannan R, Kumar K, Sahal D, Kukreti K, Chauhan VS: Reaction of artemisinin with haemoglobin: implications for antimalarial activity. Biochem J. 2005, 385: 409-418. 10.1042/BJ20041170.
Stepniewska K, Price RN, Sutherland CJ, Drakeley CJ, von Seidlein L, Nosten F, White NJ: Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J. 2008, 7: 249-10.1186/1475-2875-7-249.
White NJ: Qinghaosu: the price of success. Science. 2008, 320: 330-334. 10.1126/science.1155165.
Dondorp A, Nosten F, Stepniewska K, Day N, White N, South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-725. 10.1016/S0140-6736(05)67176-0.
Krishna S, Bustamante L, Haynes RK, Staines HM: Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008, 29: 520-527. 10.1016/j.tips.2008.07.004.
Kindermans JM, Vandenbergh D, Vreeke E, Olliaro P, D'Altilia JP: Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs). Malar J. 2007, 6: 91-10.1186/1475-2875-6-91.
Cohen JM, Singh I, O'Brien ME: Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies. Malar J. 2008, 7: 200-10.1186/1475-2875-7-200.
De Ridder S, Kooy van der F, Verpoorte R: Artemisia annua as a self-reliant treatment for malaria in developing countries. J Ethnopharmacol. 2008, 120: 302-314. 10.1016/j.jep.2008.09.017.
Kindermans JM, Pilloy J, Olliaro P, Gomes M: Ensuring sustained ACT production and reliable artemisinin supply. Malar J. 2007, 6: 125-10.1186/1475-2875-6-125.
Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo TJ, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004, 430: 900-904. 10.1038/nature02779.
Benoit-Vical F, Lelièvre J, Berry A, Deymier C, Dechy-Cabaret O, Cazelles J, Loup C, Robert A, Magnaval JF, Meunier B: Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob Agents Chemother. 2007, 51: 1463-1472. 10.1128/AAC.00967-06.
Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J, Chang MC, Withers ST, Shiba Y, Sarpong R, Keasling JD: Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature. 2006, 440: 940-943. 10.1038/nature04640.